Lance Alstodt
Net Worth

Last updated:

What is Lance Alstodt net worth?

The estimated net worth of Mr. Lance Alstodt is at least $675,863 as of 15 Sep 2023. He owns shares worth $289,943 as insider and has received compensation worth at least $385,920 in BioRestorative Therapies, Inc..

What is the salary of Lance Alstodt?

Mr. Lance Alstodt salary is $64,320 per year as Chairman, Pres & Chief Executive Officer in BioRestorative Therapies, Inc..

How old is Lance Alstodt?

Mr. Lance Alstodt is 54 years old, born in 1971.

What stocks does Lance Alstodt currently own?

As insider, Mr. Lance Alstodt owns shares in one company:

Company Title Shares Price per share Total value
BioRestorative Therapies, Inc. (BRTX) Chairman, Pres & Chief Executive Officer 189,505 $1.53 $289,943

What does BioRestorative Therapies, Inc. do?

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

BRTX logo
BRTX
BioRestorative Therapies, Inc.
$1.53

Lance Alstodt insider trading

BioRestorative Therapies, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 2,200 $1.7 $3,740
Purchase
Common Stock 800 $1.53 $1,226
Purchase
Common Stock 2,887 $1.96 $5,659
Purchase
Common Stock 4,200 $2.44 $10,248
Purchase
Common Stock 400 $3.1 $1,241
Purchase
Common Stock 200 $3.01 $602
Purchase
Common Stock 100 $3.17 $317
Purchase
Common Stock 100 $3.1 $310
Purchase
Common Stock 100 $3.09 $309
Purchase
Common Stock 100 $3.1 $310
Purchase
Common Stock 200 $3.13 $626
Purchase
Common Stock 100 $3.08 $308
Purchase
Common Stock 100 $2.99 $299
Purchase
Common Stock 200 $3.02 $604
Purchase
Common Stock 1,800 $2.99 $5,375
Purchase
Common Stock 1,000 $2.88 $2,877
Purchase
Common Stock 100 $2.99 $299
Purchase
Common Stock 100 $2.85 $285
Purchase
Common Stock 700 $2.95 $2,065
Purchase
Common Stock 1,100 $3.1 $3,408
Purchase
Common Stock 600 $3.73 $2,238
Purchase
Common Stock 700 $3.68 $2,577
Purchase
Common Stock 500 $3.91 $1,956
Purchase
Common Stock 100 $3.92 $392
Purchase
Common Stock 100 $3.98 $398
Purchase
Common Stock 100 $4.28 $428
Purchase
Common Stock 200 $4.6 $920
Purchase
Common Stock 2,700 $3.52 $9,493
Purchase
Common Stock 200 $3.96 $792
Purchase
Common Stock 200 $3.94 $787
Purchase
Common Stock 1,470 $3.4 $4,998
Purchase
Common Stock 2,000 $3.85 $7,700
Purchase
Common Stock 799 $5.5 $4,395
Purchase
Common Stock 2,500 $6 $15,000
Purchase
Common Stock 396 $6.31 $2,499
Purchase
Common Stock 4,500 $6.67 $30,024
Purchase
Common Stock 20,000 $0.24 $4,860
Purchase
Common Stock 10,000 $0.26 $2,620
Purchase
Common Stock 10,000 $0.27 $2,700
Purchase
Common Stock 10,000 $0.24 $2,400

BioRestorative Therapies key executives

BioRestorative Therapies, Inc. executives and other stock owners filed with the SEC: